CG
MCRB icon

Cutler Group’s Seres Therapeutics MCRB Stock Holding History

Cutler Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-325
Closed -$17K – 4042
2023
Q3 		$17K Buy
325
+200
+160% +$15.3K ﹤0.01% 2149
2023
Q2 		$2K Buy
+125
New +$13.6K ﹤0.01% 3054
2021
Q4 		– Sell
-260
Closed -$2K – 5796
2021
Q3 		$2K Buy
+260
New +$50.9K ﹤0.01% 5042
2018
Q2 		– Sell
-50
Closed -$5K – 4590
2018
Q1 		$5K Hold
50
– – ﹤0.01% 3288
2017
Q4 		$3K Buy
+50
New +$10.3K ﹤0.01% 3968
2017
Q2 		– Sell
-45
Closed -$7K – 6762
2017
Q1 		$7K Sell
45
-5
-10% -$1.01K ﹤0.01% 4403
2016
Q4 		$9K Sell
50
-1,470
-97% -$321K ﹤0.01% 4321
2016
Q3 		$34K Buy
1,520
+1,230
+424% +$432K ﹤0.01% 2855
2016
Q2 		$12K Sell
290
-60
-17% -$35.2K ﹤0.01% 3936
2016
Q1 		$86K Sell
350
-150
-30% -$78.3K 0.01% 1747
2015
Q4 		$64K Buy
+500
New +$329K ﹤0.01% 2208

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's MCRB Position: Q4 2023 in Review

Cutler Group sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 311 shares — an estimated $14K sold.

Cutler Group first reported a position in MCRB in Q1 2016 and held it in 30 quarters. The position peaked at $186K in Q3 2020. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Cutler Group reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 311 Seres Therapeutics shares in Q4 2023, an estimated $14K.
  • Cutler Group first reported a position in Seres Therapeutics in Q1 2016 and held it in 30 quarters.
  • Cutler Group's Seres Therapeutics position peaked at $186K in Q3 2020.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.